No profile data available.
Kairos Pharma, Ltd. (KAPA) is a healthcare company in the additional cancer treatment drugs industry, based in Los Angeles, United States, with about 1 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$5.45 million. Its market capitalization was $2.74 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
Kairos Pharma reported $0 in revenue for fiscal year 2025.
$2.74 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Indaptus Therapeutics, Inc. (INDP), Silexion Therapeutics Corp (SLXN), Mustang Bio, Inc. (MBIO), BioAtla, Inc. (BCAB).